Nkgen Biotech, Inc.
Clinical trials sponsored by Nkgen Biotech, Inc., explained in plain language.
-
New hope for Alzheimer's? Long-Term safety trial of SNK01 launches
Disease control Recruiting nowThis study is for people with Alzheimer's disease who have already taken part in a previous SNK01 study. It will test the long-term safety of SNK01, a potential treatment, and look for early signs it might help with thinking and memory. About 30 participants will receive the trea…
Phase: PHASE2 • Sponsor: NKGen Biotech, Inc. • Aim: Disease control
Last updated May 26, 2026 12:13 UTC
-
Could a cell infusion slow Alzheimer's? new trial begins
Disease control Recruiting nowThis early-stage trial tests a new treatment called SNK01 in 36 people with moderate Alzheimer's disease. The treatment is given as an IV infusion every 3 weeks for up to a year. Researchers want to see if it is safe and if it can improve thinking, memory, and daily function.
Phase: PHASE1, PHASE2 • Sponsor: NKGen Biotech, Inc. • Aim: Disease control
Last updated May 26, 2026 12:12 UTC